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Atypical antipsychotics in the treatment 
of pathological aggression in children and adolescents: 
literature review and clinical recommendations
Abstract
Objective: To review the literature about the use of atypical 
antipsychotics in the treatment of pathological aggression in 
children and adolescents. 
Method: The databases MEDLINE, SciELO, and LILACS were 
searched for publications in Portuguese or English from 1992 
to August 2011 using the following keywords: mental disease, 
child, adolescent, treatment, atypical antipsychotic, aggressive 
behavior, aggression, and violent behavior.
Results: Sixty-seven studies of good methodological quality and 
clinical interest and relevance were identified. Studies including 
children and adolescents were relatively limited, because few 
atypical antipsychotics have been approved by the Food and Drug 
Administration (FDA). All the medications included in this review 
(risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole 
and clozapine) have some effectiveness in treating aggression in 
children and adolescents, and choices should be based on clinical 
indications and side effects.
Conclusions: There are few studies about the effectiveness and 
safety of atypical antipsychotics for the pediatric population, 
and further randomized controlled studies with larger groups of 
patients and more diagnostic categories, such as severe conduct 
disorder and oppositional defiant disorder, should be conducted 
to confirm the results reported up to date and to evaluate the 
impact of long-term use.
Keywords: Aggression, violence, atypical antipsychotics, behavioral 
disorders, children, adolescents.
Resumo
Objetivo: Realizar uma revisão sistemática da literatura científica 
sobre o uso de antipsicóticos atípicos (APAs) no tratamento da 
agressividade patológica em crianças e adolescentes.
Método: Foi realizada busca eletrônica nas bases de dados 
MEDLINE, SciELO e LILACS, de 1992 a agosto 2011, considerando 
artigos publicados em língua inglesa e portuguesa. Foram 
utilizadas associações das seguintes expressões: mental disease, 
child, adolescent, treatment, atypical antipsychotic, aggressive 
behaviour, aggression e violent behavior.
Resultados: Foram identificados 67 artigos de boa qualidade 
metodológica, de relevância e interesse clínico para o tema em 
foco. De modo geral, os estudos são relativamente limitados para 
esta faixa etária, resultado do fato de poucos APAs terem sido 
aprovados pela Food and Drug Administration (FDA). Dentre as 
medicações consideradas nesta revisão (risperidona, olanzapina, 
quetiapina, ziprazidona, aripiprazol e clozapina), todas elas 
podem ter alguma efetividade no tratamento da agressividade 
em crianças e adolescentes, ficando a escolha baseada na 
indicação clínica e perfil de efeitos colaterais. 
Conclusão: O número ainda limitado de estudos acerca da 
efetividade e segurança na população pediátrica demanda 
pesquisas futuras com grupos maiores de pacientes e com mais 
categorias diagnósticas (como, por exemplo, as formas graves 
de transtorno de conduta e transtorno desafiador de oposição), 
desenhadas de forma randomizada e controlada. Assim poderão 
ser confirmados os achados até o momento e o impacto do uso 
em longo prazo.
Descritores: Agressão, violência, agentes antipsicóticos, transtornos 
do comportamento, infância, adolescência.
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Introduction
Pathological aggression or morbid aggressive behaviors 
may be symptoms of numerous mental disorders that 
affect children and adolescents. It is the main cause 
of visits to psychiatric emergence services and of 
hospitalizations of children and adolescents in specialized 
psychiatric wards.1-3 It is classified as a psychopathological 
symptom when not an adaptive behavior, as well as when 
it clearly clashes with cultural standards of the social 
group to which the child or adolescent belongs.4
Neurobiologically, impulsive/affective aggression may 
be explained as a lack of equilibrium between prefrontal 
mechanisms of top-down control (orbitofrontal cortex 
and anterior gyrus cinguli) and the bottom-up limbic 
stimuli (amygdala and other limbic areas), in which 
several neurotransmitters, such as serotonin, dopamine, 
noradrenalin and others, may be involved and may, 
therefore, be managed pharmacologically.5,6
Several studies have demonstrated that aggression 
is a result of the combination of socioenvironmental, 
psychological and biological factors, and that an 
environment favorable to personal development 
may modulate unfavorable genetic characteristics.7,8 
However, biological factors of aggressive behaviors may 
and should be carefully managed because of probable 
mid- and long-term impairments and the progression 
into severe psychiatric disorders in adulthood.9-11
Clinically, aggression is usually approached in one of 
two ways: primarily approaching the underlying psychiatric 
disorder, or directly approaching the aggressive behavior 
as the main clinical sign of the outlying disorder and the 
main treatment target.12
According to Pappadopulos et al., 40% of the children 
and adolescents hospitalized and receiving treatment to 
control aggression were administered two or more drugs, 
and most often one of them as an atypical antipsychotic 
(AAP). Other drugs used were anticonvulsants, lithium, 
psychostimulants, selective serotonin reuptake inhibitors 
(SSRI), anxiolytics, alpha-agonists, beta-blockers and 
other sedative drugs.13
This study reviewed the scientific literature to analyze 
studies about pharmacological treatments using AAP 
for impulsive and affective aggression in children and 
adolescents, regardless of their underlying disease and 
the different treatments of this symptom, and to describe 
results and possible limitations. Moreover, at the end of 
the review, the authors make clinical suggestions that 
may be useful for healthcare professionals involved in 
providing mental health care to children and adolescents.
Predatory or proactive aggression has not been 
included in this study because it has a different meaning 
and demands a specific approach, different from the 
one used for impulsive or affective aggression. So far, 
studies have found little evidence of the benefits of 
pharmacological interventions in predatory aggression, 
which is more often found in environments of the justice 
system.12
Up to the time when this study was written, no review 
of this topic had been found in the literature. Therefore, 
this review may be useful as a basis for the use of AAP in 
the psychiatric and pediatric clinical practice.
Method
MEDLINE, SciELO and LILACS databases were 
searched for articles in English or Portuguese published 
from 1992 to August 2011. The search included studies 
about pharmacological treatments of aggression in the 
different diseases and syndromes that affect children 
and adolescents.
Combinations (AND, OR, NOT) of the following 
keywords were used for the search: mental disease, 
child, adolescent, treatment, atypical antipsychotic, 
aggressive behavior, aggression, violent behavior.
Although the number of studies about the use of 
antipsychotic drugs for children and adolescents has 
increased, few controlled studies have been conducted, 
because of the high withdrawal rates, short duration 
of interventions, and sample selection biases.14 Some 
studies with adults have been used as the basis for 
the initial tests with children and adolescents, but our 
review classified them only as parameters for a careful 
analysis of results, particularly for topics still not studied 
in the pediatric population, such as the risk of metabolic 
changes.15
Of the 77 studies retrieved, 67 were selected because 
of their higher methodological quality and greater 
relevance and clinical interest for the topic under study. 
The studies were selected by all the authors together, 
and all had access to abstracts. After that, the full 
articles were divided into two groups: clinical results and 
adverse events.
Inclusion criteria were: 1) randomized, placebo 
controlled studies; 2) case reports of children and 
adolescents, or of adults that were used as the basis for 
the administration of AAP to children and adolescents; 
3) review of studies about aggression and its treatment.
This review did not establish grades of evidence (as 
defined by task forces), but only identified differences 
between controlled clinical studies (randomized, double-
blind), case series reports and clinical experience (lowest 
level of consistency).
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Results
Overall, the predominant view is that educational and 
psychosocial approaches should be implemented first 
and should not be discontinued after the introduction of 
medication.13,16
At the same time, the first medication used should be 
directed to the primary diagnosis, and only one drug should 
be used whenever possible. In the case of nonsuccess and 
when there are risks to the patients or the people that 
live with them, the treatment should include approaches 
directed to the aggressive behavior specifically.12,17-19
The use of psychopharmacologic drugs for patients 
in this age group should take into consideration the 
characteristic of their metabolism, drug pharmacokinetics 
and pharmacodynamics, and the risk of specific drug 
interactions. Children and adolescents, in general, are rapid 
metabolizers and, therefore, need antipsychotic doses that 
are proportionally higher in relation to their weight.20 
Despite a significant increase in the use of AAP for 
children and adolescents in the last years,21 up to the 
time this study was concluded only four AAP had its use 
in the pediatric population approved by the Food and 
Drug Administration (FDA) (latest update on August 
2011, according to www.fda.gov), as shown in the table 
below (Table 1). 
Although not recommended by FDA, the first four AAP 
in Table 1 have been studied by several authors in the 
last decade. They investigated the control of aggression 
in conduct disorder and classified these medications 
as safe and efficient despite their side effects and the 
limitations of their studies.22
The use of AAP should be seen as a first tool to control 
aggression when non-pharmacological approaches fail.13 
Several studies have compared the use of AAP and 
typical antipsychotics (TAP) in adolescents and young 
individuals and found that AAP should be the first choice 
because they have fewer side effects and lower risks 
of tardive dyskinesia, neuroleptic malignant syndrome, 
cognitive impairments and extrapyramidal symptoms 
(EPS),23-25 although the consequences of the metabolic 
and endocrine changes due to the use of AAP have not 
been clarified, especially not in children and adolescents.1
According to the November 2003 consensus of the 
American Association of Psychiatry and the American 
associations of endocrinologists and the associations 
for the study of diabetes and obesity, AAP had a clear 
benefit in psychiatric treatments. However, caution 
was recommended, and its use should be constantly 
monitored because of the risks of metabolic and 
hormonal disorders and weight gain.26
Studies have not found differences in the response 
to treatment between different AAP, and the choice of a 
specific drug should be based on patient tolerability and 
adverse events, the most common of which are weight 
gain, drowsiness, EPS and hyperprolactinemia.27 All AAP 
may cause drowsiness, particularly at high doses, and, 
because of that, AAP should be carefully administered: 
the dose should be accurately adjusted, and its toxicity 
and drug interactions should be re-evaluated at short 
time intervals.28
Although the occurrence of EPS due to the use of 
AAP among young patients is not negligible, it is less 
frequent than that of TAP.29 In studies designed to 
investigate schizophrenia starting in childhood, among 
AAPs, clozapine and quetiapine have been associated 
with lower rates of EPS, similarly to what is observed 
among adults.30,31 
According to the Treatment Recommendations for the 
Use of Antipsychotics for Aggressive Youth (TRAAY), based 
on studies available and specialist consensus, treatment 
should begin with low doses that are then increased 
gradually, and its efficacy should be evaluated at the most 
two weeks later. In the case of risperidone, the mean dose 
   Schizophrenia Bipolar affective disorder Irritability in Conduct
Drugs  (13-17 year-olds) (10-17 year-olds) autism disorder*
   FDA ANVISA FDA ANVISA FDA ANVISA FDA ANVISA
Risperidone + + + + + + - -
       (5-16) (5-16) 
Aripiprazole + + + + + + - -
       (6-17) (6-17) 
Olanzapine + + + + - - - -
     (13-17) (13-17) 
Quetiapine + + + + - - - -
Clozapine - - - - - - - -
Table 1 – Atypical antipsychotics approved for use in children and adolescents by the FDA 
and the Brazilian ANVISA and their indications
ANVISA = Brazilian National Health Surveillance Agency; FDA = U.S. Food and Drug Administration.
* Neither FDA nor ANVISA has any regulation about the use of drugs for the diagnostic category conduct disorder or to control aggression for any undefined 
diagnosis.
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to control aggression is smaller than (about half) the dose 
necessary to control psychotic symptoms, differently from 
clozapine, in which case the mean dose to treat aggression 
is similar to that of antipsychotic drugs, as seen in Table 
2. Data about ideal doses to control aggression are not 
available for other AAP (Table 2).13
Studies about AAP are still limited, and, therefore, 
special attention should be paid to possible adverse 
events and interactions with other medications. Still 
according to the TRAAY Part II recommendations, vital 
signs, weight, prolactin levels and metabolic changes 
should be constantly monitored, and ECG should be 
used to monitor patients at regular intervals during 
dose adjustment, because cardiac changes are dose-
dependent.13,32
In the analysis of metabolic changes (weight gain, 
risk of diabetes and dyslipidemia), studies with adults 
found that there are differences between the several 
AAP medications, although results are still relatively 
discordant, according to Table 3.26
Risperidone
Two double-blind studies with children and 
adolescents, one with a group of individuals with conduct 
disorder and the other with conduct disorder associated 
with subaverage intelligence, compared risperidone and 
placebo and found that risperidone is a well-tolerated 
and efficacious medication for aggression.33,34
Those studies found that the most common adverse 
events were drowsiness, headache and weight gain. The 
symptoms of aggression were controlled in 3 to 4 weeks 
using a mean dose of 1.5 mg/day, which was effective in 
the control of aggression for the next six months when 
compared with the placebo group.22,33,34
In the analysis of safety of its use for long periods of 
time, five studies investigated the use of risperidone in a 
total of 700 children and adolescents aged 5 to 15 years 
and found no influence on growth or sexual maturity, 
although there were changes in the levels of prolactin.35
A retrospective study including 80 individuals with 
autism who used risperidone to control aggression or 
impulsivity found that over 60% had a positive result after 
six months of treatment. The most common adverse effect 
was weight gain, followed by drowsiness, the adverse event 
most often associated with treatment discontinuation.36
A review37 has demonstrated that these findings are 
confirmed in double-blind, placebo-controlled studies 
and case reports of autism and pervasive developmental 
disorders, in which aggression was a relatively serious 
symptom. In a double-blind study with 101 children 
with autism who were administered a mean dose of 
1.8 mg/day of risperidone, 69% of the children were 
classified as responders after eight weeks, whereas 
only 12% in the placebo group responded satisfactorily. 
The most common adverse event was weight gain 
and hypersalivation, and there were no differences in 
EPS and tardive dyskinesia between groups.38 Similar 
results were found in a placebo-controlled study with 79 
children, in which the mean dose was 1.2 mg/day.39
The comparison with other AAPs revealed that 
risperidone was the medication that resulted in the highest 
prolactin elevation among adults with schizophrenia (n = 
218) in a study that followed up patients for five years.40
    Aggression Psychotic symptoms
 Drugs  Starting dose (mg) Child Adolescent Child Adolescent
Risperidone 0.25-0.5 1.5-2 2-4 3-4 3-6
Clozapine 6.5-25 150-300 200-600 150-300 200-600
Table 2 – Differences between atypical antipsychotic active doses and the impact on aggression and psychotic symptoms
Source: Adapted from TRAAY–II, table 3 of Pappadopulos et al.13
Drugs	 Weight	gain	 Risk	of	diabetes	 Worsened	lipid	profile
Clozapine +++ + +
Olanzapine +++ + +
Risperidone ++ D D
Quetiapine ++ D D
Aripiprazole* +/- - -
Ziprasidone +/- - -
Table 3 – Atypical antipsychotics and risk of secondary metabolic changes in adults
Source: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes, 2004.26
* New drugs with limited long-term follow-up studies.
+ = increase; - = no effect; D = discordant results.
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Olanzapine
An open-label prospective trial was conducted with 
16 adolescents with disruptive behavioral disorders and 
subaverage intelligence. Olanzapine was effective in the 
control of irritability when used at a mean dose of 13.7 
mg/day, but weight gain led to treatment discontinuation 
in 4 of the 16 cases.41
Similar findings were reported in a review of medical 
charts of 23 adolescents with conduct disorder and no 
response to other treatments. Olanzapine was efficacious 
in 60% of the patients, and the most common adverse 
events were weight gain and sedation.42 A double-blind, 
open-label prospective study of aggression control 
in autism and other autistic disorders found similar 
results.43 
In a study that compared the use of olanzapine with 
that of haloperidol in 12 children with autism for six 
weeks, olanzapine was more efficacious in the control of 
aggression, but resulted in greater weight gain.44
In some emergency situations that require aggression 
control, the IM injection of a rapid-acting medication 
may be necessary. Ziprasidone and olanzapine may be 
used in such cases, and their safety and efficacy has 
been demonstrated for use in adults in randomized 
double-blind studies.45,46 However, no data from clinical 
controlled studies are available to support the IM 
administration of AAP to children and adolescents.
  
Quetiapine
A study conducted by Findling et al. with 17 
moderately aggressive children with a diagnosis of 
conduct disorder for 8 weeks found that quetiapine was 
efficacious and well tolerated at a mean dose of 150 mg/
day. The most frequent adverse events were fatigue 
and weight gain. No EPS or changes in prolactin levels 
were found during the study,47 which continued with nine 
children for another 26 weeks. Positive results in the 
control of aggression were seen along all this time, and 
mean weight gain was 2.3 kg.48
An open-label prospective study with 24 aggressive 
adolescents with a diagnosis of attention deficit 
hyperactivity disorder and conduct disorder, who did not 
respond satisfactorily to treatment with methylphenidate 
alone, found that 79% improved their pattern of aggression 
when administered a maximum dose of 600 mg/day. The 
most common adverse event was drowsiness, and mean 
weight gain was 1.2 kg after nine weeks.49
The results of quetiapine in the control of aggression 
in autism have been heterogeneous. In an open-label 
study with six children receiving a mean dose of 225 
mg/day for four months, only two had improvements in 
their pattern of aggression.50Another open-label study 
with nine adolescents used doses of 100 to 450 mg/day 
for 12 weeks. Only six adolescents completed the study, 
and only two of them were responders in the analysis 
of aggression.51 In the two studies, the most common 
adverse events were drowsiness and weight gain, the 
reasons why three patients discontinued treatment.
Ziprasidone
Few studies have been published about the use of 
ziprasidone in children and adolescents. In a case series 
with 12 children with autism or other autistic disorders 
who received doses of 20 to 120 mg/day for at least 
six weeks, six children were responders for the control 
of aggression, as well as of agitation and irritability. 
Sedation was the most common adverse event, and 
weight gain was found in only one child. Five children lost 
weight, which was associated with the discontinuation of 
previous medication that had resulted in weight gain.52
For emergency situations in the control of aggression, 
ziprasidone has an additional resource, which is an IM 
rapid-acting formulation, as described above,45 although 
no controlled studies or clinical reports have evaluated 
its use in children or adolescents. 
Aripiprazole
In a case series with five children and adolescents 
with autism who received doses of 10 to 15 mg/day for a 
mean time of 12 weeks, all five were judged responders 
for aggression control, as well as for agitation and 
irritability. Sedation was a transient adverse event, 
and weight changes were variable: two children lost 
weight, which was associated with the discontinuation of 
previous medication that had resulted in weight gain.53 
Similar results were replicated in another case series 
with 32 children and adolescents with a diagnosis of 
autism, autistic disorders and mental retardation, who 
received a mean dose of 10.55 mg/day for six to 15 
months. There was a reduction in target symptoms 
(aggression, impulsivity, hyperactivity and self-injury) 
in 56% of the cases. Sedation was the most frequent 
adverse effect, and there were no significant changes in 
body weight.54
Clozapine
Few studies have evaluated the use of clozapine, 
particularly because of the risk of agranulocytosis and the 
need of rigorous monitoring of blood cell counts, which 
is a laborious task because of the little collaboration of 
children and adolescents, depending on their disease.37
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In an open-label study about the impact of clozapine 
on treatment-refractory aggression in 20 children and 
adolescents with schizophrenia, the use of emergency 
medication and seclusion events were analyzed after 
the introduction of clozapine and compared with the 
previous period of time. Clozapine had greater efficacy 
than other AAP or TAP. Patients were evaluated for at 
least six months, and mean clozapine dose on the 12th 
week was 405 mg/day. The study found a decrease in 
the frequency of administration of injectable medication 
and seclusion.55
Two series of case reports of patients with autism 
and severe treatment-refractory aggression previously 
receiving other medications found that clozapine was 
efficacious for most cases when administered at mean 
doses of 200 and 400 mg/day. In the first study, 
three patients aged 8 to 12 years had a significant 
improvement of aggression, hyperactivity and irritability 
with the administration of 100 to 200 mg/day. In the 
second study, the pattern of aggression improved for 
a 17-year-old patient receiving a mean final dose of 
275 mg/day. The major adverse events in the three 
studies were drowsiness, constipation, weight gain and 
hypersalivation.56,57 
The analysis of the risk of agranulocytosis suggests 
that children may run a greater risk than adults.58 In 
an open-label retrospective study with 172 children 
(schizophrenia: 139; bipolar disorder: 25; others: 
2) using clozapine, 13% had neutropenia, and one, 
agranulocytosis. In the same study, the most common 
adverse events were weight gain and changes in lipid 
metabolism.59
The safety of clozapine in relation to the levels of 
prolactin in children and adolescents was greater than 
that of other AAPs. A double-blind study with 35 children 
and adolescents with a diagnosis of schizophrenia 
compared clozapine with haloperidol and olanzapine and 
found that the three substances increased the levels of 
prolactin, but clozapine led to increases that were still 
within normal levels. After six weeks of treatment, all 
ten patients receiving haloperidol had increases above 
the normal limits, and seven of the ten using olanzapine 
had similar increases, but none of the 15 patients using 
clozapine had increases above the normal range.32
According to current TRAAY recommendations, if all 
other treatment options fail to control severe aggression, 
the use of clozapine should be considered in cases of 
schizophrenia and bipolar disorder in children and 
adolescents, despite the fact that clozapine has not yet 
been approved by FDA for use in these two age groups. 
There are no explicit recommendations for its use, and 
it has not even been studied for aggression in severe 
conduct disorders, although its potential usefulness 
seems plausible because of data from studies with other 
diagnostic groups.13,60,61 Pappadopulos et al. suggested 
that, if the response is only partial, the combination of 
clozapine and a mood stabilizer should be considered. 
However, such recommendation is not supported by 
studies with children and adolescents specifically.13
Table 4 shows data about the scientific studies 
included in this review, which administered AAP to 
children and adolescents to control aggression. The 
studies were divided into case reports, open-label trials 
and controlled (randomized or double-blind) studies.
Discussion
The treatment of pathological aggression, both in 
clinical practice and in research, is a great challenge, 
particularly when in its severe or extreme forms in children 
and adolescents. The establishment of an adequate 
and accurate psychiatric diagnosis, and therefore, the 
administration of the best possible treatment, involves a 
considerable degree of complexity. In these age groups, 
ethical issues regarding the treatment of people still in a 
stage of full development and who still have to be legally 
represented by their guardians becomes particularly 
difficult, complex and a matter of concern for clinicians.
The studies included in this review, particularly those 
conducted with children and adolescents, have several 
limitations as a consequence of that, in addition to the 
effects of comorbidities, multiplicity of drugs taken, 
and the necessary association with other therapeutic 
approaches, such as parental guidance, psychoeducation, 
institutional and environmental management, legal 
counseling and others. 
The limitations of clinical and research results 
are associated with the small number of patients, 
who are usually studied in case series reports, with 
the heterogeneity of the diagnostic groups under 
study, with the short follow-up time14 and, finally, 
with the large dependence on adult clinical data and 
psychopharmacology, as the psychiatry of children 
and adolescents often only “borrows” data from adult 
psychiatry because it has not yet autonomously generated 
consistent knowledge based on original and carefully 
conducted studies. Despite these limitations, these 
studies allow us to reach some tentative conclusions.
The development of more modern and safer medications 
has given rise to different ways to deal with the aggressive 
behaviors of children and adolescents.12 There does not 
seem to be any doubt about the use of medication as a 
necessary intervention, particularly in severe and extreme 
cases. Studies have already demonstrated that severe 
aggression may result in significant harm to patients 
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and their families and favor the development of serious 
psychiatric disorders in adulthood.9,10
AAPs seem to be good tools, and there is evidence 
that they are safe medications for use in children and 
adolescents with different diagnosis,13,22-25 in addition to 
being effective in the control of aggression in adults.15,62-64
Studies with children and adolescents that used these 
medications, particularly for patients with schizophrenia 
and autism, reported favorable results.55,57,65 However, 
only longitudinal prospective studies will be able to 
demonstrate the real impact of AAP on this population, 
particularly in terms of metabolic and hormone changes1,26 
associated with growth and development, although 
adverse events are well tolerated and manageable.27-29,66
Studies that analyzed metabolic changes, such 
as weight gain, dyslipidemia and the risk of diabetes, 
have recommended that these medications should be 
used carefully, and that a proactive attitude should be 
adopted, with systematic monitoring using laboratory 
tests, weight control and nutritional interventions.13,14,29,32 
Studies about the treatment of pathological 
aggression, particularly severe or extreme forms of it, 
in children and adolescents, remain limited. Therefore, 
there are no solid scientific bases for clinical decisions 
at a higher degree of safety. However, this is a topic 
of strategic relevance and that should be broadly 
investigated. In addition to methodological issues, these 
studies raise both clinical and ethical research problems, 
as they involve children and adolescents. 
Particularly important are the ethical and political-
ideological issues that pharmacological control of severe 
pathological aggression raises in clinical practice and in 
research with children and adolescents. It should always 
be stressed that pharmacological interventions should 
mandatorily be combined with careful psychosocial 
evaluations and approaches, such as parental and family 
counseling, psychotherapy, psychoeducation, school 
guidance and environment management, interventions 
that should be, whenever possible, based on controlled 
studies that have evaluated their short- and long-term 
efficacy.
There are few randomized, double-blind studies 
specifically designed to evaluate aggression control in 
children and adolescents, particularly severe aggression 
and in individuals with autistic and conduct disorders. 
Recommendations and suggestions of 
psychopharmacological management
All the medications included in this review (risperidone, 
olanzapine, quetiapine, ziprasidone, aripiprazole and 
clozapine) seem to have some degree of effectiveness 
   Risperidone Olanzapine Quetiapine Ziprasidone Aripiprazole Clozapine
Schizophrenia      
 CR/OL - - - - - N = 1
        (n = 23)55
 CS  - - - - - -
Autism      
 CR/OL - N = 2 N = 2 N = 1 N = 2 N = 2
    (n = 8)43 (n = 6)50 (n = 12)52 (n = 5)53 (n = 3)56
    (n = 12)44 (n = 9)51  (n = 32)54 (n = 1)57
 CS/OL N = 3 - - - - -
   (n = 80)36
   (n = 101)38
   (n = 79)39 
Conduct disorder      
 CR/OL - N = 2 N = 2 - - -
    (n = 16)41 (n = 16)47
    (n = 23)42 (n = 24)*49 
 CS  N = 2 - -  - -
   (n = 118)33   -
   (n = 10)34  
Mental retardation      
 CR/OL - - - - + (n = 18) + (n = 8)
 CS  + (N = 1) - - - - -
Table 4 – Case reports, open-label trials or controlled studies about the use of atypical antipsychotic drugs in children and 
adolescents to control aggressive behaviors
- = no studies; CR = case report; CS = controlled (randomized or double-blind) study; n = number of cases; N = number of studies; OL = open label trial. 
* Conduct disorder + attention deficit hyperactivity disorder.
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for children and adolescents, despite the limitations 
discussed in the text. Except for clozapine, studies did not 
find differences in their potency, and choices should be 
based on their adverse events.27 
The most common adverse events after the use of AAP 
were two: drowsiness and weight gain. Risperidone was 
more frequently associated with increases in prolactin 
levels,40 and the use of ziprasidone was only partially 
associated with weight gain.52 Data about quetiapine and 
aripiprazole are still too limited to provide a minimally 
consistent evaluation of their adverse events.47-51,53,54
As clozapine has a specific profile of action and adverse 
events, and its efficacy in treating aggression has already 
been demonstrated,15,55,64 it should become the focus of 
more detailed investigations.13,61,67 Case report findings 
are favorable for the control of aggression in patients with 
schizophrenia, autism and mental retardation. Adverse 
events have been monitored and controlled in a relatively 
safe way.56,57,59,62 Although clozapine has not been formally 
approved by FDA for use in children and adolescents, 
the clinical experience of the authors suggests that 
it may be an important tool in the control of severe or 
extreme aggression in cases in which the control of this 
symptom may be fundamental for successful planning 
and treatment. This is often the case of children and 
adolescents with severe forms of conduct disorders.
 
Conclusion
The limited number of studies about the efficacy and 
safety of AAP use in the pediatric population warrants 
future studies with larger groups of patients and more 
diagnostic categories, such as severe forms of conduct 
disorder and oppositional defiant disorder. Future studies 
may confirm findings reported to this date, as well as the 
impact of the use of these drugs in the long term. 
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